Form 8-K AERIE PHARMACEUTICALS For: Sep 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
RBC Capital Boosts PT on Aeri Pharma (AERI) to $44 Following Rhopressa Phase 3 Data
September 17, 2015 9:00 AM EDTRBC Capital lifts its price target on Outperform-rated Aerie Pharmaceuticals (Nasdaq: AERI) from $31 up to $44 following news that Rhopressa Phase 3 met its primary endpoint.
Analyst Michael J. Yee noted the following key points:
Safety is in-line and not too different from Rocket 1. Hyperemia is a known side effect and it was higher in the BID than the QD arm; however, of the 35% with increased redness, 83% scored as mild... MoreAerie Pharma (AERI) Announces Rhopressa Phase 3 Met Primary Efficacy Endpoint
September 16, 2015 4:04 PM EDTAerie Pharma (NASDAQ: AERI) reported the successful results of its second Phase 3 trial for Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial achieved its primary efficacy endpoint demonstrating non-inferiority of Rhopressa compared to timolol, the most widely used comparator. Management will host a conference call and provide accompanying slides to discuss these results at 5:00 p.m. ET today.
Rhopressa Phase 3 Highlights for Rocket 2
Rhopressa, dosed both once-daily and twice-daily, achieved its primary... More